Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Sudeep Pharma IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1989 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 626.5 Cr
Profile
Price Range 563  to  593 per share
Profile
Min Investment ₹593
Profile
Lot Size 1
Profile
Face Value ₹1
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

We are a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and are dedicated to contributing to the global healthcare ecosystem. We leverage our inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in our operations. We have established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.We are one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual manufacturing capacity of 65,579 metric tons (“MT”), as of December 31, 2024. (Source: F&S Report) As of the same date, one of our Manufacturing Facilities has been approved by the United States Food and Drug Administration (“USFDA”) for the manufacture of mineral-based ingredients. We are one of the largest exporters of mineral ingredients for pharmaceutical, food and nutrition industries from India to global markets in terms of volume of products exported during 2024 as of December 31, 2024. (Source: F&S Report) We were the only company in India and one of nine companies globally with certification of suitability issued by the Council of Europe (“CEP”) and written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient (“API”) in the European Union as of December 31, 2024. (Source: F&S Report) We are one of the pioneers in India to introduce a product range of liposomal ingredients for nutrient absorption and stability. Read More

Basic Info

Face Value 1 per share

Price 563  to  593 per share

P/E (x) 46.3

Sales( Cr.) 502

PAT( Cr.) 139

EPS 12.8

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Sujit Jaysukh Bhayani Avani Sujit Bhayani Shanil Sujit Bhayani Sujeet Jaysukh Bhayani HUF Riva Resources Pvt Ltd. Bhayani Family Trust

Pre Issue Share Holding 89.37%

Post Issue Share Holding 76.15%

Listing Details:

Listing Price: 733.95

Listing Gain: 19.2%

Current Price: 742.2

Gain On Issue: 742.2 | 0%

GMP: 121

GMP %: 20.4 %

IPO Tentative Timetable

Opening Date Nov 21, 2025
Closing Date Nov 25, 2025
Allotment Nov 26, 2025
Refund Nov 27, 2025
Delivery of Shares Nov 27, 2025
Listing Date Nov 28, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 25 14,825
Retail (Max) 13 325 192,725
S-HNI (Min) 14 350 207,550
S-HNI (Max) 67 1675 993,275
B-HNI (Min) 68 1700 1,008,100

Objective of the Issue

(i)Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I (ii)General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 3018550 643188450 213.1x
NII 2263913 264240450 116.7x
Retail 5282463 82671250 15.7x
EMP 0 0 0x
Total 10564926 990100150 93.7x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Sudeep Pharma Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 123 215 343 429 459 502
Other Income 3 3 7 10 6 9
Total Income 126 219 350 438 465 511
Total Expenditure 98 171 276 339 277 311
Operating Profit 29 48 75 100 189 200
Interest 1 1 2 6 5 7
Depreciation 3 4 5 8 9 11
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 25 43 69 86 175 183
Provision for Tax 7 10 18 24 42 44
Profit After Tax 18 33 50 62 133 139
Adjustments 0 0 0 0 0 0
Profit After Adjustments 18 33 50 62 133 139
Adjusted Earnings Per Share 1.9 3.4 5.2 6.4 13.7 14.3

Sudeep Pharma Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 81 114 163 223 356 493
Minority's Interest 0 0 0 0 0 0
Borrowings 8 14 28 20 11 40
Other Non-Current Liabilities 5 5 5 6 9 9
Total Current Liabilities 37 80 147 171 137 175
Total Liabilities 131 213 344 420 514 717
Fixed Assets 60 68 137 158 180 189
Other Non-Current Assets 15 46 10 31 58 103
Total Current Assets 56 99 197 230 275 424
Total Assets 131 213 344 420 514 717

Sudeep Pharma Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 4 4 12 21 10 14
Cash Flow from Operating Activities 10 35 -3 48 66 49
Cash Flow from Investing Activities -22 -40 -38 -50 -49 -79
Cash Flow from Financing Activities 12 13 51 -10 -13 53
Net Cash Inflow / Outflow -0 8 10 -11 4 23
Closing Cash & Cash Equivalent 4 12 21 10 14 37

Sudeep Pharma Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 1.86 3.43 5.17 6.42 13.72 14.26
CEPS(Rs) 2.17 3.8 5.63 7.23 14.65 15.35
DPS(Rs) 0 0 0 0 0 0
Book NAV/Share(Rs) 8.34 11.76 16.82 23 36.67 50.48
Core EBITDA Margin(%) 20.64 20.49 19.67 21.03 39.73 38.05
EBIT Margin(%) 20.75 20.45 20.5 21.4 39.09 37.8
Pre Tax Margin(%) 20 20 20 20.05 38.06 36.42
PAT Margin (%) 14.66 15.5 14.63 14.54 29 27.63
Cash Profit Margin (%) 17.16 17.14 15.95 16.38 30.96 29.74
ROA(%) 13.79 19.41 18.03 16.33 28.54 22.54
ROE(%) 22.28 34.17 36.15 32.24 45.98 32.75
ROCE(%) 25.25 35.71 35.85 33.22 48.76 35.84
Receivable days 89.96 72.54 86.25 85.4 94.68 119.94
Inventory Days 28.18 22.88 28.73 45.77 54.67 70.98
Payable days 69.83 59.3 63.28 68.31 100.79 133.44
PER(x) 0 0 0 0 0 0
Price/Book(x) 0 0 0 0 0 0
Dividend Yield(%) 0 0 0 0 0 0
EV/Net Sales(x) 0.14 0.1 0.19 0.17 0.14 0.19
EV/Core EBITDA(x) 0.61 0.43 0.85 0.74 0.33 0.47
Net Sales Growth(%) 0 74.86 59.46 24.99 7.12 9.3
EBIT Growth(%) 0 72.3 59.86 30.49 95.67 5.68
PAT Growth(%) 0 84.83 50.46 24.23 113.71 4.13
EPS Growth(%) 0 84.83 50.46 24.24 113.71 3.98
Debt/Equity(x) 0.25 0.27 0.51 0.37 0.21 0.27
Current Ratio(x) 1.54 1.25 1.34 1.35 2.01 2.43
Quick Ratio(x) 1.28 1.03 1.09 0.93 1.53 1.69
Interest Cover(x) 27.51 45.43 40.89 15.87 37.92 27.49
Total Debt/Mcap(x) 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 9% 14% 32% 0%
Operating Profit CAGR 6% 39% 47% 0%
PAT CAGR 5% 41% 51% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 33% 37% 36% 34%
ROCE Average 36% 39% 38% 36%

Company Contact Information

Sudeep Pharma Ltd.

Dimple Ashwinbhai Mehta

91 265 284 0656

cs.sudeep@sudeepgroup.com

129/1/ A, G. I. D. C. Estate Nandesari

IPO Lead Manager(s)

Sudeep Pharma Ltd.

ICICI Securities Ltd

IIFL Capital Services Ltd.

Registrar Info

Sudeep Pharma Ltd.

MUFG Intime India Pvt Ltd.

C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai (Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra

+91 810 811 8484

91-022-49186060

rnt.helpdesk@in.mpms.mufg.com

https://in.mpms.mufg.com/

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!